Passage Bio (PASG) Earnings Analysis

Passage Bio (PASG) next reports earnings on 2026-08-11, consensus EPS -2.64667 USD. Last quarter (2026-03-03) it missed with EPS -4.08 USD vs -2.19 USD est (-86.3%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -0.42.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PASG next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-2.64667 USD
Revenue estimaten/a

PASG earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-03-4.08 USD-2.19 USD-86.3%Miss
2025-11-10-2.44 USD-2.64 USD+7.6%Beat
2025-08-12-2.96 USD-4 USD+26%Beat
2025-03-04-0.2 USD-0.21 USD+4.8%Beat
2024-08-08-0.26 USD-0.31 USD+16.1%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

PASG valuation and analyst view

Trailing P/E-0.42
Trailing EPS-11.75221 USD
Price / book1.34
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (6 buy / 5 hold / 0 sell)
Avg price target10 USD

Related research pages

Frequently asked questions

When is Passage Bio (PASG)'s next earnings date?

Passage Bio is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -2.64667 USD.

Did PASG beat earnings last quarter?

In its 2026-03-03 report, PASG posted EPS of -4.08 USD versus a -2.19 USD estimate — a miss of 86.3%.

What is PASG's earnings track record?

Over the last 5 reported quarters with consensus data, PASG beat estimates 4 times (80%).

What is PASG's current P/E ratio and EPS?

PASG trades at a trailing P/E of -0.42 on trailing EPS of -11.75220673602702 USD.

What do analysts rate PASG?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 6 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 10 USD.